Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms

被引:3
作者
Witten, Taylor [1 ]
Staszkiewicz, Julia [1 ]
Gold, Logan [2 ]
Granier, Mallory A. [2 ]
Klapper, Rachel J. [3 ]
Lavespere, Gabriel [4 ]
Dorius, Bradley [4 ]
Allampalli, Varsha [4 ]
Ahmadzadeh, Shahab [4 ]
Shekoohi, Sahar [4 ]
Kaye, Alan D. [4 ]
Varrassi, Giustino [5 ]
机构
[1] Louisiana State Univ Hlth Sci Ctr, Sch Med, Shreveport, LA USA
[2] Louisiana State Univ, Sch Med New Orleans, New Orleans, LA USA
[3] Louisiana State Univ Hlth Sci Ctr, Dept Radiol, Shreveport, LA 71115 USA
[4] Louisiana State Univ Hlth Sci Ctr, Dept Anesthesiol, Shreveport, LA 70112 USA
[5] Paolo Procacci Fdn, Dept Pain Med, Rome, Italy
关键词
snris; ssris; non-hormonal therapy; hormonal therapy; menopause; vasomotor symptoms; QUALITY-OF-LIFE; HOT FLASHES; BREAST-CANCER; DOUBLE-BLIND; HORMONE-THERAPY; VENLAFAXINE; MENOPAUSE; MANAGEMENT; PLACEBO; ESTRADIOL;
D O I
10.7759/cureus.52467
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An average of 60-80% of all menopausal women experience bothersome vasomotor symptoms (VMSs), such as flushing and sweating, within the first seven years of onset. However, despite increasing prevalence, these hot flashes remain hard to treat and have a negative effect on the quality of life. Though hormone replacement therapy is commonly utilized as a standard treatment for VMSs, this therapy is not recommended for all women. Specifically, the oral form of hormone replacement therapy is associated with several contraindications, including a history of thromboembolic disease, migraine headache with aura, liver failure, heart disease, and hormone-dependent cancers. For women with these medical conditions, current literature indicates that nonhormonal therapies such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are suitable alternatives to reduce the frequency and intensity of VMSs. Currently, the only SSRI that is FDA-approved for the treatment of VMSs is paroxetine, but studies show that fluoxetine, citalopram, escitalopram, and sertraline are also proven to provide similar benefits. Similarly, the SNRI venlafaxine has also been well tolerated and has been shown to reduce the frequency and severity of hot flashes. The present investigation reviews the physiology of VMSs and examines the evidence for the use of nonhormonal pharmacologic therapies as treatment for women experiencing hot flashes. These interventions should be considered whenever hormone replacement therapy is contraindicated, with therapy individualized based on the severity of symptoms.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Vasomotor Symptoms Across the Menopause Transition Differences Among Women
    Avis, Nancy E.
    Crawford, Sybil L.
    Green, Robin
    [J]. OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2018, 45 (04) : 629 - +
  • [32] Management of vasomotor symptoms in cancer patients
    Zhu, Ling
    Hshieh, Tammy T.
    Iyer, Tara K.
    Morgans, Alicia K.
    Hamnvik, Ole-Petter R.
    [J]. ONCOLOGIST, 2025, 30 (02)
  • [33] Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms
    Hager, Marlene
    Goldstein, Tal
    Fitz, Victoria
    Ott, Johannes
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2024, : 783 - 789
  • [34] Effects of resistance training on quality of life in postmenopausal women with vasomotor symptoms
    Berin, E.
    Hammar, M.
    Lindblom, H.
    Lindh-Astrand, L.
    Holm, A-C Spetz
    [J]. CLIMACTERIC, 2022, 25 (03) : 264 - 270
  • [35] The Relationship between Vitamin D and Vasomotor Symptoms During the Postmenopausal Period
    Arslanca, Tufan
    Korkmaz, Hilal
    Arslanca, S. Banu
    Pehlivanoglu, Bilge
    Celikel, Ozgul
    [J]. CLINICAL LABORATORY, 2020, 66 (07) : 1285 - 1290
  • [36] Acupuncture for menopausal vasomotor symptoms: study protocol for a randomised controlled trial
    Pirotta, Marie
    Ee, Carolyn
    Teede, Helena
    Chondros, Patty
    French, Simon
    Myers, Stephen
    Xue, Charlie
    [J]. TRIALS, 2014, 15
  • [37] Phytoestrogen Treatment for Menopausal Vasomotor Symptoms after Breast Cancer
    Vogel, Marie
    Franik, Sebastian
    Kiesel, Ludwig
    [J]. BREAST CARE, 2023, 18 (03) : 158 - 162
  • [38] Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society
    Carpenter, Janet
    Gass, Margery L. S.
    Maki, Pauline M.
    Newton, Katherine M.
    Pinkerton, JoAnn V.
    Taylor, Maida
    Utian, Wulf H.
    Schnatz, Peter F.
    Kaunitz, Andrew M.
    Shapiro, Marla
    Shifren, Jan L.
    Hodis, Howard N.
    Kingsberg, Sheryl A.
    Liu, James H.
    Richard-Davis, Gloria
    Santoro, Nanette
    Sievert, Lynnette Leidy
    Schiff, Isaac
    Pike, Caitlin
    Allen, Penny
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2015, 22 (11): : 1155 - 1174
  • [39] Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety
    Archer, David F.
    Dupont, Caroline M.
    Constantine, Ginger D.
    Pickar, James H.
    Olivier, Sophie
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 200 (03) : 238.e1 - 238.e10
  • [40] Managing vasomotor symptoms in women after cancer
    Pinkerton, J. V.
    Santen, R. J.
    [J]. CLIMACTERIC, 2019, 22 (06) : 544 - 552